Conversations in Drug Development Trends

AUGUST 29, 2024

By: Nathan Chadwick, Therapeutic Strategy Lead, Rare Disease Over the last few years in clinical trials, particularly within the rare disease community, a notable shift is underway, where patients and caregivers are taking the lead in reaching out to clinical trial sites rather than the other way around.

Clinical Trials 52

Clinical Trials Trials Disease Drug Development 52

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

Conversations in Drug Development Trends

JULY 8, 2024

By: Lisle Kingery, PhD, Therapeutic Strategy Lead, Neuroscience With depression rates at an all-time high and limited new treatments available, depression clinical trials are more important than ever. Treatment Treatment can take various forms, including therapy, medication, a combination of both, or a clinical trial.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. Five Strategies to Tailor Your Pediatric Clinical Trials to the Child’s Needs 1.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

PPD

OCTOBER 17, 2024

There has also been an increase in government and regulatory support for CGT trials, in conjunction with an increase in investments for these products to get to market. Site selection presents barriers and opportunities As cell therapies expand in Asia-Pacific, areas with large hospitals are often the main hubs for innovation.

Therapies 52

Therapies Clinical Trials Clinical Research Trials 52

PPD

NOVEMBER 7, 2023

Food and Drug Administration (FDA) draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.” Diversity in Dermatologic Disease Prevalence, Presentation and Outcomes Skin conditions affect all skin types and all racial and ethnic groups.

Clinical Trials 59

Clinical Trials Trials Clinical Research Disease 59

PPD

JUNE 29, 2023

Although several corticosteroid treatments are available as first-line treatments, drug developers continue to seek more effective therapies to improve the wellbeing of those diagnosed with atopic dermatitis. But developing treatments for atopic dermatitis is complex and competitive.

Clinical Trials 52

Clinical Trials Trials Drug Development Clinical Research 52

PPD

JANUARY 5, 2023

In an industry survey led by PPD, Thermo Fisher Scientific’s clinical research business, rare diseases emerged as a top therapeutic area in drug developers’ pipelines, with 39% of global biotech and biopharma leaders pursuing therapies in the broad rare disease space.

Disease 52

Disease Trials Clinical Trials Clinical Research 52

PPD

JULY 29, 2024

In today’s data-driven world, AI has become valuable and indispensable, enabling organizations to extract valuable insights from vast amounts of data, make informed decisions and drive innovation across different sectors — including drug development.

Clinical Research 98

Clinical Research Clinical Trials Research Trials 98

PPD

MAY 18, 2023

Yet, four out of five care partners of people with neurodegenerative disorders have never been informed of clinical trial opportunities , according to a survey of more than 250 caregivers conducted by PPD, the clinical research business of Thermo Fisher Scientific. There’s little time to lose.

Clinical Trials 86

Clinical Trials Trials Clinical Research Doctors 86

The Pharma Data

OCTOBER 30, 2020

Beyer will present psychometric findings from the first-ever, multi-center trial conducted in patients with trichotillomania – an impulse control disorder marked by repetitive hairpulling behaviors. . Promentis’ drug development efforts are focused on a unique approach to addressing glutamatergic imbalance.

Pharmaceuticals 52

Pharmaceuticals Therapies Drug Development Trials 52

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . United States and virtually from July 26 to 30, 2021 (Presentation No.:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

Drug Target Review

MAY 7, 2024

However, some biomarkers may only be present in a minority of patients, requiring a large patient population to identify such markers. How do AI-enhanced approaches accelerate the drug development process for rare diseases? In 2020, 78 percent of orphan drugs and biologics approved were targeted therapies.

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

Drug Target Review

AUGUST 28, 2024

The preclinical findings, together with the early evidence of tolerability and efficacy coming from the MATCH Phase I study, laid the foundations for our characterisation and engineering platform, used to develop Resolution Therapeutics’ lead product, which will be tested in patients starting later this year.

Therapies 115

Therapies Disease Engineering Medical Schools 115

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous.

Therapies 105

Therapies Drug Development Disease Clinical Development 105

DrugBank

JULY 20, 2023

Rare diseases, therefore, present compelling opportunities for Drug Development. Since each disease is present in small groups of patients, this research is also fraught with complex challenges. We're excited to expand our data offering by launching a new Rare Disease add-on to complement our Clinical Trial dataset.

Disease 74

Disease Clinical Trials Trials FDA 74

Conversations in Drug Development Trends

OCTOBER 24, 2023

While this is a small number of people in each rare disease patient community, the significant and continued growth of rare disease drug development is unsurprising given that there are over 10,000 rare diseases , with more being discovered every year.

Clinical Trials 52

Clinical Trials Disease Therapies Drug Development 52

PPD

JUNE 20, 2024

Acceleration in every step of clinical research is critical to pharmaceutical developers. Despite advances in technology and innovation, pharmaceutical leaders say that trials are increasingly complex, particularly when it comes to patient recruitment and site engagement. With a median delay of 12.2

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

Alta Sciences

JULY 25, 2024

Discover some of the nonclinical requirements for moving dermal studies into Phase I clinical trials, including formulation considerations, species selection, and ideal candidates for transdermal drug delivery systems (TDDS). Watch the poster presentation. Read or listen now. Watch the webinar. the UK, or the EU.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

The Pharma Data

JANUARY 7, 2021

(RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Rakuten Medical’s Chairman and CEO, Hiroshi “Mickey” Mikitani, is scheduled to present virtually at approximately 4:30 a.m.

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

The Pharma Data

JULY 8, 2021

The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below ( italics to note updated language). Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

MAY 5, 2022

1 Clinical trials for new therapies in AML are becoming increasingly lengthy to complete based on the traditional clinical endpoint of survival. The consortium looks to continue to bring together its expertise with those in the field through joint advisory boards, congress presentations and other scientific engagements.

Disease 52

Disease Clinical Trials Drug Development Pharmaceutical Companies 52

Alta Sciences

JULY 26, 2023

Exploring a Novel Method to Determine Antisense Oligonucleotides (ASOs) shajjar Wed, 07/26/2023 - 10:00 HTML This presentation shares a highly efficient method for determining antisense oligonucleotides (ASOs) in human blood. WATCH PRESENTATION Speak with one of our bioanalytical experts to find out how we can support you.

Clinical Trials 40

Clinical Trials Drug Development Trials Research 40

Conversations in Drug Development Trends

NOVEMBER 10, 2023

At this year’s annual Pain Therapeutics Summit , which took place in San Diego, CA, October 19 to 20th, I heard brilliant presentations on novel pain medication development, targeted discoveries, pain classifications, the NIH HEAL Initiative , trial designs, biomarkers, and others.

Clinical Trials 75

Clinical Trials Trials Compliance Treatment 75

Conversations in Drug Development Trends

SEPTEMBER 20, 2023

Our team has been working diligently to find a way to revitalize how we use automation, and during WRIB this year, we presented a poster on “Revolutionizing Bioanalysis through Automation: Overcoming Challenges and Unlocking Potential.” ” In case you missed it, we’ve highlighted the top four takeaways: 1.

Clinical Trials 87

Clinical Trials Laboratories Trials 87

Alta Sciences

OCTOBER 30, 2023

Discover the considerations and assessments necessary for performing preclinical research for ophthalmic therapies in this new eBook, that covers everything you need to know, from species selection and routes of administration, to preparing for first-in-human trials. Read it now. The Altascientist : Issue No. Read or listen now. Listen here.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

biobide

FEBRUARY 2, 2024

Zebrafish Pioneers Advance in Pediatric Cancer Research and Treatment Increasing the survival rate is the primary goal when screening for cancer drugs. Some pediatric cancers, such as leukemias, present a high survival percentage with the available treatment regimens but cause systemic toxicities, and a subset of patients eventually relapse.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

LifeSciVC

JULY 11, 2023

The meeting brings together tens of thousands of physicians, scientists, patients, advocates, innovators, and those involved in oncology drug development from around the world in order to explore the latest advances in cancer treatment, clinical trials, and translational and clinical research.

Therapies 67

Therapies Trials Clinical Development Science 67

The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

Conversations in Drug Development Trends

APRIL 5, 2024

As we continue to work tirelessly to advance rare disease treatments, improve clinical trial quality, and increase access to life-saving therapies, we hope to have the chance to meet you, work with you, or elevate your voice. We will be at WODC April 24th-25th and hope to see you there ! Our Juliane K.

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Target Review

MAY 27, 2024

How does the company see antibody-drug conjugates (ADCs) fitting into this approach? Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

PPD

OCTOBER 4, 2023

Running a clinical trial is a long and tumultuous process requiring trial sites and sponsors to sift through various challenges. Identifying, preempting and overcoming emerging issues and bottlenecks, reducing site burden, and improving the overall efficiency of a trial through continued improvements are just a few examples.

Clinical Trials 52

Clinical Trials Trials Compliance Laboratories 52

The Pharma Data

JANUARY 27, 2021

Based on these results, we will now move to identify the recommended Phase II dose for the Phase IIa part of the trial and look forward to further evaluating the exciting potential of BI-1206 to bring much needed innovation to lymphoma patients,” said Martin Welschof, Ph.D, (Nasdaq: CASI), a U.S. CEO of BioInvent. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

MARCH 27, 2023

The Independent Data Monitoring Committee recommended stopping the trial early as the primary endpoint of invasive disease-free survival (iDFS) has been met. President, Global Drug Development and Chief Medical Officer, Novartis.

Trials 40

Trials Treatment Disease Research 40

Pharmaceutical Development Group

DECEMBER 19, 2021

Effective use of Real World Data (RWD) and Real World Evidence (RWE) can reduce costs of Pharmaceutical Drug and Biologic Products and Process Development, Drug Development Services , expedite a FDA Pre-Submission Review, and lead to FDA Approval. Spanogle, Ph.D.

FDA Approval 52

FDA Approval FDA Clinical Trials Drug Development 52